Biotech Values

[flatlander_60048]

Personally, I think the offer is fair since NVS is undervalued relative to long term valuation metrics. I think the fourth qtr earnings will provide guidance which will narrow the gap between the 2.8 share NVS per 1 ACL offer and the $180 offered to Nestle. By the time the deal with the minority shareholders closes (i.e., mid year), the deal will not look as one sided.


FL